Companies › Alcon Research
2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Ophthalmology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Apraclonidine Adrenergic receptor alpha-2 agonist | ADRA2A, ADRA2C, ADRA2B | Phase 3 | Ocular Hyperemia | Jan 2027 |
| AR-14034 SR implant Unclear - presumed long-acting intravitreal implant | – | Phase 1 | Neovascular Age-related Macular Degeneration (nAMD) | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07578363 | Apraclonidine | Phase 3 | Ocular Hyperemia | Ophthalmology | Jan 2027 |
| NCT07531043 | Apraclonidine | Phase 3 | Ocular Hyperemia | Ophthalmology | Feb 2027 |
| NCT05769153 | AR-14034 SR implant | Phase 1 | Neovascular Age-related Macular Degeneration (nAMD) | Ophthalmology | Apr 2027 |
Santen SAS PolyActiva Taejoon Pharmaceutical Bausch & Lomb Huons
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.